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Abstract
The use of fenfluramines can increase the risk of developing pulmonary arterial hypertension (PAH) in humans, but the
mechanisms responsible are unresolved. A recent study reported that female mice lacking the gene for tryptophan
hydroxylase-1 (Tph1(2/2) mice) were protected from PAH caused by chronic dexfenfluramine, suggesting a pivotal role for
peripheral serotonin (5-HT) in the disease process. Here we tested two alternative hypotheses which might explain the lack
of dexfenfluramine-induced PAH in Tph1(2/2) mice. We postulated that: 1) Tph1(2/2) mice express lower levels of
pulmonary 5-HT transporter (SERT) when compared to wild-type controls, and 2) Tph1(2/2) mice display adaptive changes
in the expression of non-serotonergic pulmonary genes which are implicated in PAH. SERT was measured using radioligand
binding methods, whereas gene expression was measured using microarrays followed by quantitative real time PCR (qRT-
PCR). Contrary to our first hypothesis, the number of pulmonary SERT sites was modestly up-regulated in female Tph1(2/2)
mice. The expression of 51 distinct genes was significantly altered in the lungs of female Tph1(2/2) mice. Consistent with
our second hypothesis, qRT-PCR confirmed that at least three genes implicated in the pathogenesis of PAH were markedly
up-regulated: Has2, Hapln3 and Retlna. The finding that female Tph1(2/2) mice are protected from dexfenfluramine-
induced PAH could be related to compensatory changes in pulmonary gene expression, in addition to reductions in
peripheral 5-HT. These observations emphasize the intrinsic limitation of interpreting data from studies conducted in
transgenic mice that are not fully characterized.
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Introduction
Fenfluramine and dexfenfluramine (fenfluramines) are anorectic
medications that were removed from clinical use. Epidemiological
findings have revealed that these drugs increase the risk for two serious
cardiovascular side-effects, valvular heart disease (VHD) and
pulmonary arterial hypertension (PAH). Most evidence indicates that
fenfluramine-induced VHD involves the activation of 5-HT2B
receptors localized on heart valves by the metabolite norfenfluramine
[1], whereas the mechanisms responsible for PAH remain unresolved.
Based on the fact that fenfluramines are well-established
substrates for 5-HT transporter (SERT) proteins, we proposed a
‘‘gateway hypothesis’’ to explain fenfluramine-induced PAH [2].
According to this proposal, SERT proteins localized to pulmonary
smooth muscle cells provide gateways for fenfluramines to
accumulate inside of cells, where drug molecules then promote
mitogenesis via mechanisms that may include direct posttransla-
tional transamination of small proteins [3,4]. In support of this
hypothesis, it is well established that SERT-mediated uptake of 5-
HT can induce mitogenic responses in pulmonary smooth muscle
cells [5,6] and similar pathways are activated by fenfluramine itself
[7].
An alternative proposal to explain fenfluramine-associated PAH
is known as the ‘‘5-HT hypothesis’’ [8]. A key prediction of this
hypothesis is that fenfluramine administration increases plasma 5-
HT to micromolar (mM) concentrations required to produce
vasoconstriction and mitogenesis, which then leads to the
development of PAH. Using a novel microdialysis method to
measure plasma concentrations of 5-HT in rat whole blood
samples, we directly tested the 5-HT hypothesis. Our findings
show that acute and chronic administration of fenfluramine can
increase plasma concentrations of 5-HT, but the elevations are far
below those necessary to produce cardiovascular side-effects
[9,10]. Thus, direct assessment of plasma 5-HT suggests that the
5-HT hypothesis cannot explain the pathology of fenfluramine-
induced PAH.
Recently, investigators have used knockout mice which lack the
gene for tryptophan hydroxylase-1 (Tph1(2/2) mice) to examine
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the role of 5-HT in mediating dexfenfluramine-induced PAH [11].
Tryptophan hydroxylase-1 is the chief enzyme responsible for synthesis
of peripheral 5-HT [12], and Tph1(2/2) mice display markedly
reduced concentrations of 5-HT in whole blood (92% decrease),
platelets (90% decrease) and plasma (80% decrease) [13,14,15].
Dempsie et al. [11] reported that chronic oral administration of
dexfenfluramine (5 mg/kg/day) for 28 days produces PAH in wild-
type (WT) female mice but not in Tph1(2/2) female mice. Curiously,
dexfenfluramine does not produce PAH in WT male mice (Dr. M.
MacLean, personal communication), demonstrating the sex-specific
nature of the observed pathology. In view of the substantial reductions
in peripheral 5-HT present inTph1(2/2) mice, the authors concluded
that dexfenfluramine fails to produce PAH due to lack of peripheral
5-HT.
There are caveats to interpreting the effects of dexfenfluramine
in Tph1(2/2) mice. First, Dempsie et al. [11] never actually
measured plasma 5-HT in WT and Tph1(2/2) mice. There is an
assumption that dexfenfluramine would not increase plasma 5-
HT in Tph1(2/2) mice, but data from rats suggest otherwise.
Zolkowska et al. [10] showed that chronic fluoxetine administra-
tion (10 mg/kg/day) for 14 days decreased whole blood 5-HT by
nearly 80%, but acute fenfluramine still caused modest increases
in plasma 5-HT. Second, it is well known that a single gene
deletion can lead to adaptive changes in the expression of many
other genes. For instance, deletion of the gene for vasoactive
intestinal peptide (VIP) in mice causes changes in the expression
of many pulmonary genes, including those thought to contribute
to the PAH phenotype [16]. Transgenic mice that express a
truncated form of bone morphogenetic protein receptor type II
(BMPR2) demonstrate altered expression of 181 unique named
genes [17]. It seems possible that changes in the expression of
genes unrelated to 5-HT synthesis may contribute to the
protection of female Tph1(2/2) mice from dexfenfluramine-
induced PAH.
In view of the above-mentioned considerations, we tested two
hypotheses related to the lack of PAH in Tph1(2/2) mice. First,
we hypothesized that Tph1(2/2) mice express lower levels of
SERT than WT controls. A decrease in SERT expression would
be predicted to impede the entry of dexfenfluramine into cells,
thereby reducing the propensity for developing PAH. Second, we
hypothesized that Tph1(2/2) mice display compensatory changes
in the expression of genes unrelated to 5-HT synthesis that provide
protection from PAH. Our findings demonstrate that genetic
deletion of tryptophan hydroxylase-1 produces a modest up-
regulation of pulmonary SERT binding sites (i.e., 30–40%
elevation) and an increase in the expression level of several genes
implicated in the pathogenesis of PAH. Thus, the resistance of
female Tph1(2/2) mice to dexfenfluramine-induced PAH could
be related to mechanisms that do not involve decreased peripheral
5-HT.
Results
SERT binding experiments
As shown in Table 1, the binding density (BMAX) for pulmonary
SERT was increased by 30–40% in both male and female
Tph1(2/2) mice as compared to WT controls. In brain tissue,
SERT BMAX for Tph1(2/2) and WT mice was not significantly
different (Table 2). The binding experiments revealed important
sex differences in the density of SERT proteins. The pulmonary
SERT BMAX was significantly higher in males than in females,
whereas the brain SERT BMAX was lower in males than in
females.
Microarray findings
The findings summarized in Table 3 show that more than 20
genes were significantly up-regulated in Tph1(2/2) mice when
compared to WT. The most markedly up-regulated gene was
hemoglobin, beta adult minor chain (Hbb-b1). Other up-regulated
genes included hyaluronan and proteoglycan link protein 3
(Hapln3), dihydropyrimidine dehydrogenase (Dpyd), keratin 17
(Krt-17), solute carrier family 17 (sodium-dependent inorganic
phosphate co-transporter) (Slc17a8), hyaluronan synthase 2 (Has2),
and resistin like alpha (Retnla), among others. Table 4 shows the list
of 23 down-regulated genes which included G protein receptor
141 (Grp141), DNAJ (HSP40) homolog, subfamily 3 (DNAjb3), and
solute carrier family 6 (neurotransmitter transporter, L-proline),
member 7 (Slc6a7).
Quantitative real-time PCR results
We used quantitative real-time PCR to confirm the changes in
expression of three genes that have been implicated in the
pathogenesis of PAH: Has2, Hapln3 and Retnla. The first two genes
relate directly to hyaluronic acid, a component of the extracellular
matrix that has been implicated in PAH [18]. Retnla (resistin like
alpha) has also been strongly linked to PAH [19]. Consistent with
the array results, all three genes were significantly up-regulated in
the Tph1(2/2) mice in comparison the WT control mice as
depicted in Fig. 1.
Table 1. SERT Binding Parameters in Mouse Lung.
BMAX
(fmol/mg protein±SD)
KD
(nM±SD)
Females
Tph1(+/+) (WT) (n = 4) 9569 0.9760.07
Tph1(2/2) (n = 5) 131613* 0.7660.08
Males
Tph1(+/+) (WT) (n = 11) 14569# 0.7160.02
Tph1(2/2) (n = 7) 186612*{ 0.8760.05*
[125I]RTI-55 binding assays were conducted as described in METHODS.
*p,0.05 compared to the corresponding WT mouse of the same sex;
#p,0.05 when compared to the WT female mouse;
{p,0.05 when compared to the Tph1(2/2) female mouse (Student’s t-test,
p,0.05).
doi:10.1371/journal.pone.0017735.t001
Table 2. SERT Binding Parameters in Mouse Brain.
BMAX
(fmol/mg protein±SD)
KD
(nM±SD)
Females
Tph1(+/+)(WT) (n = 5) 659619 0.5160.01
Tph1(2/2) (n = 5) 692626 0.5060.01
Males
Tph1(+/+) (WT)(n = 5) 589625* 0.5160.01
Tph1(2/2) (n = 5) 618630* 0.5160.01
[125I]RTI-55 binding assays were conducted as described in METHODS.
*p,0.05 compared to the corresponding females (Student’s t-test).
doi:10.1371/journal.pone.0017735.t002
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Table 3. Microarray Results: Up-regulated Genes.
Tph1/(2/2)WT
Fold-Change Gene Symbol Common Name Description
67.18 Hbb-b2 Hbb-b1 hemoglobin, beta adult minor chain
24.57 Hapln3 Hapln3 hyaluronan and proteoglycan link protein 3
14.63 Dpyd Dpyd dihydropyrimidine dehydrogenase
14.25 Etv4 Etv4 ets variant gene 4, E1AF
13.17 Derl3 Derl3 Der1-like domain family, member 3
9.70 Fuca1 Fuca1 fucosidase, alpha-L- 1, tissue
9.68 Krt17 Krt1-17 keratin 17
9.36 Slc17a8 Slc17a8 solute carrier family 17, member 8
9.31 Rg9mtd3 Rg9mtd3 RNA (guanine-9-) methyltransferase domain containing 3
9.05 Olig1 Olig1 oligodendrocyte transcription factor 1
8.71 Ybx2 Ybx2 Y box protein 2
8.21 Il5 Il5 interleukin 5
8.00 Has2 Has2 hyaluronan synthase 2
7.86 Syt13 Syt13 synaptotagmin XIII
7.58 Lrrc9 Rik leucine-rich repeat-containing 9
7.37 Stra6 Stra6 stimulated by retinoic acid gene 6
7.11 Crygc Crygb crystallin, gamma C
2.97 Car11 Car11 carbonic anhydrase 11
2.86 Bcat2 Bcat2 branched chain aminotransferase 2, mitochondrial
2.59 Serpinh1 Serpinh1 serine (or cysteine) peptidase inhibitor, clade H, member 1
2.29 Retnla Retnla resistin like alpha
2.22 Gldc Gldc glycine decarboxylase
2.01 Luzp2 Luzp2 leucine zipper protein 2
These data were generated from lung tissue harvested from WT and Tph1(2/2) female mice (n = 6 per group). The above changes were statistically significant
(p,0.025).
doi:10.1371/journal.pone.0017735.t003
Table 4. Microarray Results: Down-regulated Genes.
Tph1(2/2)/WT
Fold-Change Gene Symbol Common Name Description
22.00 Dlc1 HP; Arhgap7 deleted in liver cancer 1
22.01 Slc6a7 Slc6a7 solute carrier family 6, member 7
22.46 Tmco7 AW413431 transmembrane and coiled-coil domains 7
24.35 Psmd8 Psmd8 proteasome 26S subunit, non-ATPase, 8
25.43 V1rh13 V1rh13 vomeronasal 1 receptor, H13
26.49 Gpr141 Gpr141 G protein-coupled receptor 141
27.09 Pdzd3 Pdzk2 PDZ domain containing 3
29.52 Foxd4 Foxd4 forkhead box D4
213.87 Crabp1 Crabp1 cellular retinoic acid binding protein I
214.29 Slc2a9 Slc2a9 solute carrier family 2 (glucose transporter), member 9
214.71 Dnajb3 Dnajb3 DnaJ (Hsp40) homolog, subfamily B, member 3
221.28 Picalm Picalm phosphatidylinositol binding clathrin assembly protein
244.44 AI451617 LOC209387 expressed sequence AI451617
2111.98 Trim30 Trim30 tripartite-motif protein 30
These data were generated from lung tissue harvested from WT and Tph1(2/2) female mice (n = 6 per group). The above changes were statistically significant
(p,0.025).
doi:10.1371/journal.pone.0017735.t004
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Discussion
Epidemiological evidence links the use of aminorex, fenflur-
amine and dexfenfluramine to the development of PAH in human
subjects [for review see [20]]. It is noteworthy that aminorex poses
a much greater risk for PAH when compared to fenfluramines, but
the underpinnings of pulmonary pathology remain unclear in both
cases. Efforts to study the mechanisms involved with anorexigen-
induced PAH have been stymied by the failure of these drugs to
reliably produce pulmonary pathology in laboratory animal
species. As reviewed by Weir [20], chronic administration of
aminorex does not produce PAH in monkeys, calves, rats or dogs.
Similarly, chronic administration of fenfluramines does not
produce PAH in male rats [21,22] or mice [23]. Given this
information, it is a remarkable finding that chronic administration
of dexfenfluramine produces PAH in female mice of the C57BL/6
strain [11]. Because female mice of this strain appear to be unique
in their response to chronic dexfenfluramine, this mouse model
could be useful for dissecting out the pathogenesis of anorexigen-
induced PAH. Indeed, it would be interesting for future studies to
compare overall gene expression patterns of male versus female
C57BL/6 mice to identify factors responsible for the sex-specific
propensity of females to develop PAH.
Dempsie et al. [11] reported that deletion of the gene for
tryptophan hydroxylase-1 in female C57BL/6 mice provided
protection from PAH produced by chronic dexfenfluramine.
Because Tph1(2/2) mice are known to have markedly lower levels
of peripheral 5-HT, a logical conclusion is that plasma 5-HT is
necessary for the development of dexfenfluramine-induced PAH in
these mice. As noted in the Introduction, two assumptions underlie
this conclusion. The first assumption is that dexfenfluramine does
not increase plasma 5-HT in Tph1(2/2) mice, a possibility that has
not been examined. Data from rats show that fenfluramine can
increase plasma 5-HT even under conditions where platelet 5-HT is
markedly reduced [10]. The second assumption was that the only
change of significance in Tph1(2/2) mice was deletion of the gene
for tryptophan hydroxylase-1. It is well documented that transgenic
mice can have compensatory changes in gene expression, so it seems
plausible that alterations in the expression of genes unrelated to 5-
HT synthesis could contribute to the failure of dexfenfluramine to
produce PAH in female Tph1(2/2) mice.
The first hypothesis tested in the present study was that
pulmonary SERT might be down-regulated in Tph1(2/2) mice.
Contrary to this proposal, SERT was modestly up-regulated in
pulmonary membranes prepared from both male and female
Tph1(2/2) mice. One simple interpretation of the SERT data is
that Tph1(2/2) mice display increased SERT BMAX in lung tissue
to maintain optimal levels of intracellular 5-HT in response to
markedly reduced plasma 5-HT. Studies have demonstrated that
SERT is expressed almost exclusively on pulmonary arteries in rat
lung (Morecroft et al. 2005), but the precise localization of SERT
in mouse lung has not been determined. Surprisingly, we found
that male C57BL/6 WT mice had a 50% higher SERT BMAX
than female WT mice of this strain, so it seems that elevated
SERT BMAX does not predispose male mice to the development of
dexfenfluramine-induced PAH. Other studies have shown that
transgenic mice over-expressing SERT (SERT+ mice) have
increased right ventricular pressure and develop PAH more
robustly in response to hypoxia than WT controls [11,24,25]. To
our knowledge, the possibility that the expression of other genes
related to the pathogenesis of PAH are altered in SERT+ mice has
not been examined.
A major finding of the present study is that expression levels of
numerous genes unrelated to 5-HT are altered in female Tph1(2/2)
mice. The data in Tables 3 and 4 demonstrate that 28 pulmonary
genes were significantly up-regulated while 23 genes were down-
regulated in Tph1(2/2) mice. Many of these changes in gene
expression exceeded 10-fold relative to WT controls. The physiolog-
ical relevance of these changes is not immediately clear, but
expression levels of specific genes related to the pathogenesis of
PAH were significantly altered. For example, it is well known that
PAH is accompanied by the turnover of extracellular matrix
constituents, including hyaluronic acid [18]. Therefore, it is notable
that Tph1(2/2) mice over-expressed genes related to hyaluronic acid
synthesis and deposition: Has2 and Hapln3. Moreover, Retnla (resistin
like alpha, HIMF, FIZZ1) was also up-regulated in Tph1(2/2) mice,
and this gene has been implicated in the development of hypoxia-
induced PAH [19,26]. As reviewed by Fan et al. [19], in vivo
knockdown of Retnla had a protective effect on hypoxia-induced
PAH, whereas over-expression of Retnla in the lung caused PAH.
Direct extrapolation of our data predicts that Tph1(2/2) mice would
be more prone to develop PAH in response to hypoxia than WT
mice. The relevance of this prediction to dexfenfuramine-induced
PAH is not clear, especially in light of the extensive changes in gene
expression observed in these mice. Viewed collectively, our data
support the hypothesis that changes in the expression of genes
unrelated to 5-HT synthesis may contribute to the absence of
dexfenfluramine-induced PAH in female Tph1(2/2) mice. It must
be noted that since whole lungs were used in our experiments,
we cannot determine which specific tissue type (vascular, endo-
thelial, pulmonary, etc.) exhibits the changes in gene expression noted
here.
In summary, the expression of numerous pulmonary genes are
altered in Tph1(2/2) mice, including some genes that have been
implicated in PAH. The physiological significance of these changes
in gene expression remains to be determined. Based on our data, it
seems reasonable to conclude that the insensitivity of female
Tph1(2/2) mice to dexfenfluramine-induced PAH could be
related to compensatory changes in non-serotonergic gene
expression, in addition to lower levels of peripheral 5-HT. These
observations emphasize the intrinsic limitation of interpreting data
from studies using transgenic mice without first performing
thorough phenotypic characterization.
Figure 1. Quantitative real-time PCR was conducted as
described in MATERIALS AND METHODS with pulmonary
tissue harvested from WT and Tph1(2/2) female mice (n=6).
*p,0.05, **p,0.001 when compared to WT (ANOVA).
doi:10.1371/journal.pone.0017735.g001
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Materials and Methods
Animals and tissue collection
Mice were maintained in IVC cages (Tecniplast Deutschland,
Hohenpeissenberg, Germany) under standardized conditions with
an artificial 12-h dark–light cycle, with free access to standard
chow (SSNIFF Spezialita¨ten, Soest, Germany) and drinking water
ad libitum. Local German authorities approved the studies with
standards corresponding to those prescribed by the American
Physiological Society. Male and female Tph1(2/2) (7 generation
backcross to C57BL/6 background) mice and corresponding
C57BL/6 controls (3.5 to 5 month old) were used for the
experiments. To collect the organs, animals were anesthetized by
intraperitoneal (i.p.) ketamine (100 mg/kg) and xylazine (50 mg/
kg) and perfused with PBS to wash out blood. Lungs and brains
were isolated and immediately snap-frozen in liquid nitrogen.
Mice were not treated with any pharmacological agents, except for
anesthetics at the time of perfusion. The animal work was
conducted according to relevant national and international
guidelines and was approved by the local authorities (Landesamt
fu¨r Gesundheit und Soziales, Berlin; approval ID: T0042/06).
Tissues were harvested in the laboratory of Dr. Bader and shipped
to the laboratory of Dr. Rothman. The lungs were not examined
in terms of pathology and appearance because no abnormalities
were noted in previous studies using these mice.
Membrane preparation for bindings assays
Whole lungs and brains were frozen at 280uuC until the day of
assay. On the day of the assay, frozen lungs or brains were prepared
as described [27] with minor modifications. The frozen tissue was
homogenized with a polytron (setting 6, 15 sec) using 10 ml of tissue
buffer (TB) per sample. The TB was 50 mM Tris-HCl, 150 mM
NaCl, 1 mM EDTA, 10 mM MgCl2, with 10% glycerol, 500 mg/
ml soybean trypsin inhibitor, 10 mMbenzamidine, 1 mg/ml each of
leupeptin, bacitracin, pepstatin A, and antipain, pH 7.4. Homog-
enized lung tissue was centrifuged at 12006g for 5 min at 4uC. The
resulting supernatant was centrifuged at 48,0006 g for 30 min at
4uC; the pellet was resuspended and centrifuged at 48,0006 g for
30 min at 4uC. The pellet was resuspended in ice cold binding
buffer (BB: 55.2 mM sodium phosphate pH 7.4) and used in the
assay. Homogenized brain tissue was centrifuged at 30,0006g for
10 min at 4uC. The pellet was resuspended and centrifuged at
30,0006g for 10 min at 4uC after which the pellet was resuspended
in BB and used in the assay. Typical protein values, as determined
by the Lowry method, were 0.05–0.07 mg/ml.
Radioligand binding procedures
SERT sites were labeled using [125I]RTI-55 (PerkinElmer Life
and Analytical Sciences, SA=2200 Ci/mmol). The binding assays
proceeded as follows. Polystyrene test tubes (12675 mm) were
prefilled with 100 ml of drug (RTI-55), 100 ml of radioligand (final
concentration,0.01 nM) and 50 ml of a ‘‘blocker.’’ The blocker was
used at a final concentration of 100 nM GBR12935 and 100 nM
desipramine to prevent [125I]RTI-55 from binding to dopamine or
norepinephrine transporters. RTI-55 and the blocker were made up
in BB containing 1 mg/ml BSA (BB/BSA). The radioligand was
made up in a protease inhibitor cocktail containing BB/BSA
(chymostatin [25 mg/ml], leupeptin [25 mg/ml], EDTA [1 mM],
EGTA [1 mM]). The assay was initiated by the addition of 750 mL
of the prepared membranes. Following an 18–20 hr incubation at
4uC, samples were filtered over Whatman GF/B filters which were
presoaked in wash buffer (ice-cold 10 mM Tris-HCl, pH 7.4
containing 150 mM NaCl) containing 2% polyethylenimine.
Nonspecific binding was determined using 1 mM indatraline.
Binding assay design, analysis, and statistics
Ten point inhibition curves were generated by displacing
[125I]RTI-55 binding using unlabeled RTI-55 (0.02–10 nM
[brain] or 0.02–82 nM [lung]). The data of several experiments
were pooled and fit to the one site binding model for the best-fit
estimates of the BMAX and KD using MLAB-PC as previously
described [28]. Statistical significance (p,0.05) between binding
parameters was determined by the Student’s t-test.
RNA extraction
Whole lung tissue was powdered under liquid nitrogen in a
mortar and pestle. Total RNA was isolated from 30 mg of
powdered tissue using Qiagen RNeasy Mini kit (Qiagen, Valencia,
CA) according to the manufacturer’s instructions. RNA integrity
was assessed using an Agilent 2100 Bioanalyzer (Agilent, Palo Alto,
CA) and showed no degradation.
Microarray hybridization, scanning, and data analysis
Microarray hybridization was carried out using Illumina’s
Mouse-ref 8 Expression BeadChips arrays (22,523 probes)
(Illumina Inc., San Diego, CA). In brief, a 600 ng aliquot of total
RNA from each pulmonary sample obtained from female C57BL/
6 WT and female Tph1(2/2) mice (n = 6) was amplified using
Ambion’s Illumina RNA Amplification kit (Ambion, Austin, TX).
Single-stranded RNA (cRNA) was generated and labeled by
incorporating biotin-16-UTP (Roche Diagnostics, Indianapolis,
IN). Seven hundred fifty ng of each cRNA sample was hybridized
to Illumina arrays at 55uC overnight according to the Illumina
Whole-Genome Gene Expression Protocol for BeadStation
(Illumina Inc.). Hybridized biotinylated cRNA was detected with
Cyanine3-streptavidin (Amersham Biosciences, Piscataway, NJ)
and quantified using Illumina’s BeadStation 500GX Genetic
Analysis Systems scanner. The microarray data reported in the
manuscript are in accordance with MIAME guidelines. The
Illumina BeadStudio software was used to measure fluorescent
hybridization signals. Data were extracted by BeadStudio
(Illumina). The array data, generated with a total of 6 mice per
group, were processed by GenomeStudio version 1.6.0. Data were
then imported and analyzed using GeneSpring software v. 7
(Silicon Genetics, Redwood City, CA, USA). A gene was identified
as changed if it showed increases or decreases in expression
according to an arbitrary cut-off of 2-fold changes at p,0.025.
Quantitative Real-time PCR
Individual total RNA obtained from 6–8 mice per group was
reverse-transcribed with oligo dT primers and RT for PCR kit
(Clontech, Mountain View, CA). PCR experiments were done
using the LightCycler 480 II (Roche, Indianapolis, IN) and iQ
SYBR Green Supermix (BioRad, Hercules, CA) according to the
manufacturer’s protocol. Sequences for gene-specific primers
corresponding to PCR targets were obtained using LightCycler
Probe Design software (Roche). The primers were synthesized and
HPLC-purified at the Synthesis and Sequencing Facility of Johns
Hopkins University (Baltimore, MD). Quantitative PCR values
were normalized using OAZ1 (a gene for ornithine decarboxylase
antizyme 1) based on the paper by De Jong et al [29].
Statistical analysis of PCR data
Statistical analysis for the PCR data was performed using
analysis of variance (ANOVA) followed by post-hoc analyses
(StatView 4.02, SAS Institute, Cary, NC). Values are shown as
means 6 SEM. The null hypothesis was rejected at p,0.05.
Altered Gene Expression in Tph1 Knockout Mice
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